Authorised Prescriber and peptides in Australia
Short answer: Authorised Prescriber is a TGA scheme granting a specific doctor ongoing approval to supply a specific unapproved medicine to a class of patients. For compounded peptides, SAS Category B is the far more common lawful route.
'Authorised prescriber' gets used loosely in peptide marketing. Here's what the TGA scheme actually is, how it differs from SAS-B and personal importation, and which pathway a legitimate Australian prescriber will use for your peptide.
Key points
- Authorised Prescriber is granted per doctor, per product, per indication — not per patient.
- SAS Category B is the usual lawful route for compounded peptides in Australia.
- Neither pathway makes an unapproved peptide an approved medicine.
- Personal importation does not legalise Schedule 4 peptides bought offshore.
- Verify the doctor on the AHPRA register rather than trusting an 'authorised prescriber' badge.
The three lawful access pathways
1. ARTG-registered medicine — approved for supply in Australia, prescribed normally (e.g. semaglutide, tirzepatide). 2. Special Access Scheme Category B — patient-by-patient access to an unapproved medicine, lodged by the prescriber. This is the usual route for compounded peptides. 3. Authorised Prescriber — practitioner-level authorisation for a specified unapproved product and patient class, with periodic TGA reporting. Anything outside these is not an 'alternative pathway'; it's unlawful supply.
Why SAS-B is the norm for peptides
Compounded peptide therapy is highly individualised: product, dose and indication vary per patient, which fits SAS-B's per-patient model. Authorised Prescriber authorisation is granted for a defined product and indication and requires ethics committee or specialist college endorsement, so it's better suited to a narrow, stable use case than to individualised compounding.
What obligations come with each pathway
Under SAS-B the prescriber lodges a notification identifying the product, indication and patient, obtains informed consent that the medicine is unapproved, monitors the patient and reports adverse events. Under Authorised Prescriber the practitioner reports the number of patients treated to the TGA every six months, keeps the authorisation current for the specified product and indication, and carries the same consent, monitoring and reporting duties. Under either pathway the doctor remains fully responsible for the clinical decision.
How to read 'authorised prescriber' in peptide marketing
The phrase is frequently used as a trust signal by sites that mean nothing more than 'a doctor writes the script'. A genuine authorisation is specific: a named practitioner, a named product, a named indication and a defined patient class. If a site claims authorised prescriber status but won't name the doctor, the product or the indication, treat the claim as unverified and ask which pathway your own prescription would actually use.
What this means for you as a patient
You don't need to choose a pathway — your doctor does, and they'll tell you which applies. What you should confirm is that a named AHPRA-registered Australian doctor is prescribing, that the lawful pathway is documented, and that a TGA-licensed Australian compounding pharmacy is dispensing.
ARTG vs SAS-B vs Authorised Prescriber
| ARTG-registered | SAS Category B | Authorised Prescriber | |
|---|---|---|---|
| Approval level | Product approved for supply | Per patient | Per practitioner, product and indication |
| TGA paperwork | None | Notification at prescribing | Six-monthly reporting |
| Typical peptides | Semaglutide, tirzepatide | BPC-157, CJC-1295, ipamorelin, GHK-Cu | Narrow specialty use |
| Patient wait added | None | None in practice | None once authorised |
| Informed consent for unapproved use | Not required | Required | Required |
| Dispensing | Community pharmacy | TGA-licensed compounding pharmacy | TGA-licensed compounding pharmacy |
FAQs
- What is a TGA Authorised Prescriber?
- Authorised Prescriber (AP) is a TGA scheme that lets a specified medical practitioner supply a specified unapproved medicine to a class of patients under their care, without notifying the TGA for each individual patient. Authorisation is granted per practitioner, per product, per indication.
- What is the difference between Authorised Prescriber and SAS-B?
- SAS Category B is patient-by-patient: the doctor lodges a notification or application for each person. Authorised Prescriber is granted up front for a class of patients, with periodic reporting to the TGA instead of per-patient lodgement. Both are lawful routes to an unapproved medicine.
- Are peptides prescribed under Authorised Prescriber in Australia?
- Occasionally, but SAS-B is the common route for compounded peptides such as BPC-157, CJC-1295 and ipamorelin. AP requires endorsement by a human research ethics committee or a specialist college and is tied to a defined product and indication, which suits established specialty use more than individualised compounding.
- Which pathway will my doctor use?
- Most PeptideDoctorAU prescriptions for unapproved peptides go through SAS-B. ARTG-registered medicines such as semaglutide and tirzepatide need neither pathway — they're prescribed normally.
- Can I import peptides myself under the personal importation scheme?
- The personal importation scheme has strict limits and does not make unlawful goods lawful. Many peptides sold offshore as 'research chemicals' are Schedule 4 substances; importing them without a valid prescription can breach the Customs Act and the Poisons Standard, and shipments are routinely seized.
- Does Authorised Prescriber status make a clinic more legitimate?
- Not by itself. What matters is a named AHPRA-registered doctor, a genuine assessment, a lawful supply pathway and an Australian licensed pharmacy. A clinic advertising 'authorised prescriber' without naming the doctor or the product is marketing, not compliance.
- How does a doctor become an Authorised Prescriber?
- The practitioner applies to the TGA for a specified unapproved product, indication and patient class, supported by endorsement from a human research ethics committee or the relevant specialist college, together with evidence of their qualifications and experience. Authorisation is granted for a defined period and carries six-monthly reporting obligations.
- Does Authorised Prescriber status make the medicine approved?
- No. The product remains unapproved and is not on the ARTG. The scheme changes how access is authorised, not the regulatory status or evidence base of the medicine, and informed consent must still make clear that the product is unapproved.
- Is SAS-B slower than Authorised Prescriber for patients?
- In practice, no. SAS Category B for most peptides is a notification the prescriber lodges at the time of prescribing, so there is no waiting period for the patient. AP saves the prescriber administrative work across a caseload; it doesn't shorten your timeline.
- What is SAS Category A and does it apply to peptides?
- Category A is a notification pathway restricted to patients who are seriously ill with a condition likely to lead to death within months, or from which premature death is otherwise likely. It rarely applies to peptide therapy, which is why Category B is the relevant pathway for almost all patients.
- Can a nurse practitioner or pharmacist use these pathways?
- SAS and Authorised Prescriber access is available to medical practitioners, and in defined circumstances to other authorised health practitioners within their scope. For peptide therapy in Australia the prescriber is an AHPRA-registered medical practitioner.
- How can I verify the pathway used for my prescription?
- Ask the prescriber directly which pathway applies to your medicine and expect a straight answer — SAS-B, Authorised Prescriber, or ARTG-registered. Then verify the doctor on the AHPRA public register and confirm the dispensing pharmacy is an Australian compounding pharmacy.
Related reading
Medically reviewed by the PeptideDoctorAU Medical Review Panel — last reviewed 29 May 2026. See the panel.
Start lawfully — $99 telehealth consult
Free 5-minute pre-qualification. If suitable, you'll be matched with an AHPRA-registered Australian doctor — TGA SAS-B prescribing, Australian-compounded vial.
Start free assessment